These poor outcomes have been attributed to the lower levels of PD-1 molecule expression on EGFR mutant NSCLC cancer cells and to the complex interactions of EGFR mutant cells with the tumor microenvironment (TME). This evidence concerns the gene EGFR and neoplasm.